Regeneron Pharmaceuticals
REGN
$676.69
-0.33%
Regeneron Pharmaceuticals is a biotechnology company that discovers, develops, and commercializes medicines for eye disease, cardiovascular disease, cancer, and inflammation. It is a leading innovator in the biotech space, with blockbuster products like Eylea and Dupixent, and a strong research-driven culture. The current investor narrative centers on the company's pipeline setbacks, particularly a Phase 3 cancer trial failure in May 2026, which has pressured the stock, but also on its robust commercial portfolio and potential for recovery through new product launches and cost discipline.…
REGN
Regeneron Pharmaceuticals
$676.69
Related headlines
REGN 12-Month Price Forecast
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Regeneron Pharmaceuticals's 12-month outlook, with a consensus price target around $820.72 and implied upside of +21.3% versus the current price.
Average Target
$820.72
0 analysts
Implied Upside
+21.3%
vs. current price
Analyst Count
—
covering this stock
Price Range
$641 - $1000
Analyst target range
The stock is covered by 27 analysts, with a consensus recommendation of 'Buy' (mean rating 1.75 on a 1-5 scale). The average target price is $820.72, implying approximately +23.5% upside from the current price of $664.45. The distribution leans bullish, with 5 Buy ratings and 1 Hold (from recent actions), and no Sell ratings. This suggests analysts see value at current levels despite recent headwinds. The target range spans from a low of $641.00 to a high of $1,000.00. The high target of $1,000 implies over 50% upside, likely assuming successful pipeline execution and margin recovery. The low target of $641 is slightly below the current price, reflecting downside risk from further pipeline failures or competitive pressures. Recent rating actions show a mix: Benchmark upgraded from Hold to Buy on July 7, while Leerink downgraded from Outperform to Market Perform on May 18, indicating some divergence in sentiment. The wide spread between low and high targets ($359) signals high uncertainty about the company's future, but the overall bullish consensus suggests analysts believe the risk/reward is favorable.
Bulls vs Bears: REGN Investment Factors
Regeneron presents a mixed picture: strong commercial execution with 19% revenue growth and a robust balance sheet, but recent pipeline setbacks and margin compression have pressured the stock. The bull case rests on attractive valuation (17.9x trailing P/E vs industry 22x) and analyst upside of 23.5%, while the bear case highlights oncology pipeline uncertainty and declining margins. Currently, the evidence slightly favors the bull case given the strong fundamentals and discounted valuation, but the key tension is whether the pipeline setback is a temporary blip or a sign of deeper R&D challenges. Resolution of this uncertainty will determine the stock's trajectory.
Bullish
- Strong Revenue Growth: Q1 2026 revenue grew 19.0% YoY to $3.605B, driven by collaboration revenue and product sales. This acceleration from prior quarters supports the investment case.
- Attractive Valuation Discount: Trailing P/E of 17.9x is below the biotech industry average of ~22x, a 19% discount. Forward P/E of 12.1x implies market expectations of earnings growth, offering potential upside.
- Analyst Consensus Buy: 27 analysts rate the stock a Buy (mean 1.75/5) with an average target of $820.72, implying 23.5% upside from $664.45. No Sell ratings indicate broad optimism.
- Robust Free Cash Flow: TTM free cash flow is $4.155B, providing significant financial flexibility for R&D, acquisitions, or shareholder returns. Q1 2026 FCF was $848M.
Bearish
- Pipeline Setback in Oncology: A Phase 3 cancer trial failure in May 2026 caused a sharp decline from ~$700 to ~$630, eroding investor confidence in the oncology pipeline. This raises uncertainty about future growth drivers.
- Margin Compression Trend: Gross margin fell to 81.4% in Q1 2026 from 85-86% in 2025, and operating margin dropped to 17.8% from 19.5% a year ago, driven by higher R&D spending ($1.645B vs $1.34B).
- High PEG Ratio: PEG ratio of 3.38 suggests the stock is expensive relative to its earnings growth rate, indicating that growth expectations may already be priced in.
- Negative Relative Strength: The stock underperformed the S&P 500 by 17.2% over 3 months and 25.1% year-to-date, reflecting persistent negative sentiment and technical weakness.
REGN Technical Analysis
The stock is in a clear downtrend over the past year, with a 1-year price change of +21.3% but a significant decline from its 52-week high of $821.11. Currently trading at $664.45, it sits at 81% of its 52-week range, indicating it is closer to the low end. This positioning suggests the stock is in a corrective phase after a prior rally, and the price action reflects ongoing negative sentiment. Short-term momentum is mixed: the 1-month change is +8.0%, showing a recent bounce, while the 3-month change is -10.9%, confirming the intermediate downtrend. The divergence between the 1-month recovery and the 3-month decline could signal a potential short-term bottom, but the longer-term trend remains bearish. The stock's beta of 0.236 indicates it is significantly less volatile than the market, meaning it may not participate fully in market rallies but also offers downside protection. Key support is at the 52-week low of $541.00, while resistance is at the 52-week high of $821.11. A break above $821.11 would signal a reversal of the downtrend, while a break below $541.00 could lead to further downside. The low beta suggests that any breakout or breakdown may be less dramatic than the broader market.
Beta
0.24
0.24x market volatility
Max Drawdown
-26.1%
Largest decline past year
52-Week Range
$541-$821
Price range past year
Annual Return
+23.0%
Cumulative gain past year
| Period | REGN Return | S&P 500 |
|---|---|---|
| 1m | +11.3% | +0.3% |
| 3m | -9.8% | +4.7% |
| 6m | -7.7% | +7.5% |
| 1y | +23.0% | +18.4% |
| ytd | -12.8% | +9.0% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
REGN Fundamental Analysis
Revenue has been growing steadily, with Q1 2026 revenue of $3.605 billion, up 19.0% year-over-year from $3.029 billion in Q1 2025. The multi-quarter trend shows acceleration: Q1 2025 growth was modest, but Q2 and Q3 2025 saw strong double-digit increases. The growth is driven by collaboration revenue ($1.9B) and product sales ($1.53B), with Eylea and Dupixent as key contributors. This robust top-line growth supports the investment case, though pipeline setbacks could temper future expectations. Profitability is solid, with Q1 2026 net income of $727 million and a gross margin of 81.4%. However, margins have compressed from the 85-86% range in 2025, partly due to higher R&D spending ($1.645B in Q1 2026 vs. $1.34B in Q1 2025). Operating margin fell to 17.8% from 19.5% a year ago, indicating cost pressures. The company remains highly profitable, but margin compression is a watchpoint. The balance sheet is strong: debt-to-equity is only 0.087, and the current ratio is 4.13, indicating ample liquidity. Free cash flow was $848 million in Q1 2026, and TTM FCF is $4.155 billion, providing significant financial flexibility. ROE is 14.4%, reflecting efficient capital use. The company generates enough cash to fund operations and R&D without relying on external financing.
Quarterly Revenue
$3.6B
2026-03
Revenue YoY Growth
+19.0%
YoY Comparison
Gross Margin
81.4%
Latest Quarter
Free Cash Flow
$4.2B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is REGN Overvalued?
Since net income is positive, the primary valuation metric is the P/E ratio. The trailing P/E is 17.9x, while the forward P/E is 12.1x, implying the market expects earnings growth. The gap between trailing and forward P/E suggests that earnings are expected to increase, which aligns with the revenue growth trajectory. Compared to the biotechnology industry average P/E of around 22x (based on sector data), Regeneron's trailing P/E of 17.9x represents a discount of about 19%. This discount may be justified by recent pipeline setbacks and margin compression, but it could also indicate undervaluation given the company's strong commercial portfolio and cash flow. Historically, Regeneron's P/E has ranged from 4.7x (Q2 2021) to 36.2x (Q1 2024). The current trailing P/E of 17.9x is near the middle of this range, suggesting it is not at extreme levels. The forward P/E of 12.1x is near the lower end of the historical band, implying that the market is pricing in conservative earnings expectations, which could present an opportunity if the company delivers upside.
PE
17.9x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range 5x~28x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
13.8x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: Regeneron's margin compression is a key risk, with gross margin declining from ~85% in 2025 to 81.4% in Q1 2026 and operating margin falling from 19.5% to 17.8%. The company's heavy R&D spending ($1.645B in Q1 2026, up 23% YoY) pressures profitability, though it is necessary for pipeline development. Revenue concentration in Eylea and Dupixent, which together account for a significant portion of product sales, exposes the company to competitive threats or patent expirations. However, the low debt-to-equity of 0.087 and strong free cash flow of $4.155B TTM mitigate financial distress risk.
Market & Competitive Risks: The stock's trailing P/E of 17.9x is below the industry average, but the PEG ratio of 3.38 suggests it is expensive relative to growth, leaving it vulnerable to multiple compression if growth disappoints. Competitive risks include biosimilars to Eylea and new entrants in immunology. The low beta of 0.236 indicates low market correlation, but the stock has underperformed the S&P 500 by 25.1% YTD, reflecting negative sentiment. Recent news of a Phase 3 cancer trial failure highlights execution risk in the pipeline, which could lead to further analyst downgrades.
Worst-Case Scenario: A further pipeline failure, such as a setback for Dupixent label expansion or Eylea competition, could drive the stock to its 52-week low of $541.00, representing a 18.6% decline from the current price of $664.45. In a severe scenario, if revenue growth decelerates below 10% and margins continue to compress, the stock could test the analyst low target of $641.00, a 3.5% downside. The maximum drawdown over the past year was -26.05%, implying a potential loss of about $173 from current levels.